Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220936
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNuñez, Alexa-
dc.contributor.authorMarras, Viviana-
dc.contributor.authorHarlander, Matevz-
dc.contributor.authorMekov, Evgeni-
dc.contributor.authorEsquinas López, Cristina-
dc.contributor.authorTurel, Matjaz-
dc.contributor.authorLestan, David-
dc.contributor.authorPetkov, Rosen-
dc.contributor.authorYanev, Nikolay-
dc.contributor.authorPirina, Pietro-
dc.contributor.authorNegri, Silvia-
dc.contributor.authorMiravitlles Fernández, Marc-
dc.contributor.authorBarrecheguren, Miriam-
dc.date.accessioned2025-05-09T17:46:50Z-
dc.date.available2025-05-09T17:46:50Z-
dc.date.issued2020-03-31-
dc.identifier.issn1176-9106-
dc.identifier.urihttps://hdl.handle.net/2445/220936-
dc.description.abstractIntroduction: Chronic obstructive pulmonary disease (COPD) is associated with increased lung and systemic inflammation. We aimed to identify associations between easy-to-obtain blood biomarkers and the frequency and severity of exacerbations. Methods: Cross-sectional, multicentre study performed in four centres in Spain, Italy, Bulgaria, and Slovenia. Blood samples were obtained for blood cell count, C-reactive protein (CRP), alpha-1 antitrypsin (AAT) and fibrinogen analysis. The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and eosinophil/basophil ratio (EBR) were calculated. Firstly, patients were divided into clinical phenotypes according to the Spanish guidelines of COPD, and secondly, patients were classified into 2 groups: non-exacerbators (≤1 ambulatory exacerbation in the previous year) and exacerbators (≥2 ambulatory exacerbations or 1 hospitalisation in the previous year). A multivariate stepwise logistic regression model was performed to identify laboratory parameters associated with exacerbators. Results: A total of 355 patients with a mean age 66 years (SD=8.9) were included, and 64% were male. The mean FEV1% (forced expiratory volume in the first second) was 55% (SD=20%), and the mean COPD Assessment Test (CAT) score was 15.6 (SD=7.9). One hundred ninety-six (55.2%) patients were classified in the non-exacerbator group, and 159 (44.8%) were exacerbators. Patients in the exacerbators group presented lower haemoglobin levels (p=0.019) and ERB (p= 0.023) but higher CRP levels (p=0.001). In the multivariate analysis, females, higher levels of CRP, lower FEV1% and low EBR were independently related to exacerbators. Conclusion: Female sex, having a more severe impairment of lung function, higher CRP levels and a lower EBR are associated with an exacerbator phenotype in COPD.-
dc.format.extent10 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherDove Medical Press-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.2147/COPD.S240720-
dc.relation.ispartofInternational Journal of Chronic Obstructive Pulmonary Disease, 2020, vol. 15, p. 681-690-
dc.relation.urihttps://doi.org/10.2147/COPD.S240720-
dc.rightscc-by-nc (c) Nuñez, Alexa et al., 2020-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/-
dc.sourceArticles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)-
dc.subject.classificationMarcadors bioquímics-
dc.subject.classificationMalalties pulmonars obstructives cròniques-
dc.subject.classificationFenotip-
dc.subject.otherBiochemical markers-
dc.subject.otherChronic obstructive pulmonary diseases-
dc.subject.otherPhenotype-
dc.titleAssociation between routine blood biomarkers and clinical phenotypes and exacerbations in chronic obstructive pulmonary disease-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec725121-
dc.date.updated2025-05-09T17:46:50Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid32280207-
Appears in Collections:Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)

Files in This Item:
File Description SizeFormat 
252178.pdf788.16 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons